Open AccessLocalized scleroderma secondary to mixed connective tissue disease during abatacept therapy
Author(s) -
Nagaoka Sayuko,
Hayashi Shujiro,
Igawa Ken
Publication year - 2022
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12215
Subject(s) - abatacept , scleroderma (fungus) , medicine , connective tissue , dermatology , connective tissue disease , adverse effect , localized scleroderma , pathology , disease , lichen sclerosus , autoimmune disease , rituximab , lymphoma , inoculation
A 47‐year‐old woman with mixed connective tissue disease was treated with abatacept. After 2 months, a 3‐cm depression with atrophied surface was observed on her back, which had histopathological consistent with the symptoms of localized scleroderma. Although some cases of paradoxical reaction or cutaneous adverse event have been reported from abatacept, no localized scleroderma has been reported, suggesting this to be a unique case.